Dear Colleagues,

After three years of very successful virtual Annual Meetings, we are thrilled to meet in person in 2024 in Bethesda. The ASENT2024 Annual Meeting will highlight the latest therapeutic advances in a broad range neurologic disease states, processes and delivery methods, including nine scientific symposia, a scientific debate, and a Covid update. A few highlights include:

On Thursday, March 14, 2024, the plenary session “Pre-clinical to First in Human in Drug Development” will feature Nathan Fountain, M.D., Thomas E. Worrell, Jr, Professor of Neurology and Epileptology at University of Virginia and Jim Doherty, Ph.D., of Sage Therapeutics to compare the similarities and differences in the preclinical process and infrastructure when developing a neurotherapeutic. As ASENT President, I will personally moderate this fireside chat style discussion.

The two additional unopposed plenary sessions will take place: “Fluid Biomarkers as Endpoints for Neurodegenerative Diseases” on Tuesday, March 12, 2024, and “Parkinson’s Disease Biological Staging and Implications for Therapeutic Trials” on Wednesday, March 13, 2024. Other unopposed sessions include “NIH Update on COVID and CNS disease” with speaker Avindra Nath, M.D., Senior Investigator, NINDS, and a Beta Amyloid Debate will be held Wednesday, March 13, 2024.

Attendees will also have an opportunity to hear top abstracts selected for presentation by the Abstract Review Committee. On Wednesday, March 13, 2024, as many as 20 selected abstracts will be presented as part of the ASENT Pipeline Datablitz. Abstracts qualify for an ASENT Pipeline Data Blitz presentation when they are submitted as an Abstract Submission. Abstracts can be submitted via https://asent.org/AnnualMeeting2024

Other special events include the Careers in Neuroscience Dinner, during which invited speakers showcase the wide range of career opportunities available in neuroscience related fields. Each presenter will take a few minutes to share an overview of their career and highlight any unique career opportunities they have discovered along the way. Participants and faculty from the Training in Neurotherapeutics Discovery and Development for Academic Scientists course also participate in this dynamic event. This reception and dinner are a wonderful way to kick off the meeting on Tuesday, March 12, 2024.

We are excited that the inaugural ASENT Training in Clinical Trials course will be held on Monday, March 12 - Tuesday, March 13, 2024, co-located with the Annual Meeting. Developed by ASENT leadership and led by outstanding faculty, this 1 ½ day course will introduce researchers and clinicians to the principles of neurotherapeutic clinical trial development and implementation.

Finally, ASENT continues its dedication to our international colleagues. We are pleased to welcome guests from the Japanese Society of Neurological Therapeutics and are honored to continue the tradition of neurological education and research among academic neurologists around the world. I, along with the Board of Directors and the Program Committee, invite you to make the most of this outstanding meeting.

Best,
Andrew J. Cole, M.D., F.R.C.P.(C.)
Harvard Medical School
President, ASENT
WHY ATTEND ASENT2024

ASENT2024 is the premier neurotherapeutics conference where senior leaders through junior faculty and trainees from across payers, providers, employers, investors, fast-growing startups, industry, academia, policymakers, funders and innovation centers gather to ask one question: how can we improve the process of the development and discovery of neurotherapeutics?

Attendees are often surprised to find that more than 50% of participants are practicing physicians and the caliber of speakers is outstanding for a conference that provides ample opportunity to connect, network and converse. Additionally the scientific content showcases the leading edge in neurotherapeutics including innovations across disease states, novel delivery systems, gene therapy, the latest drug therapies and devices. The event features plenary sessions, fireside chats, panel discussions, business roundtables, and networking meetings.

WHO ATTENDS

Clinician-Investigators
Neuroscience Trainees
Neuroscientist Researchers
Industry Research Scientists
Clinicians
Advocacy Group Leaders
Chairs of Neurology
Chief Medical Officers
Chief Scientific Officers
CEOs
Founders
Funders
Investors
Payers
Innovation Centers
CROs
Journal Editors
Health Journalists
Drug and Device Companies
Communication Companies
Health Systems
FDA
NIH
All ARE WELCOME!
50% ARE PREScribers

WHAT IS ASENT?

The American Society for Experimental Neurotherapeutics (ASENT) is an independent non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the process by which new therapies are made available to patients with neurological disorders. Its primary goal is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system.

MEETING DETAILS

ASENT 2024 Meeting Dates
Tues, March 12 - Thurs, March 14, 2024

Registration Deadline
March 12, 2024
asent.org/annualmeeting2024

Hotel Reservation Deadline
February 10, 2024

Meeting Location
Hyatt Regency Bethesda
Metro Center, 1,
Bethesda, MD 20814
asent.org/annualmeeting2024
CONFERENCE INFORMATION AT A GLANCE

CONFERENCE DATES
March 12 - 14, 2024

LOCATION
Hyatt Regency Bethesda
Bethesda, MD

REGISTRATION
Registration is open & is complimentary in most sponsorship packages.

PROGRAM
Registered sponsors are encouraged to attend all conference sessions, meals, receptions & events.

HOUSING
Discounted housing is available at the Hyatt Regency Bethesda. Rates begin at $219. Housing can be booked here: asent.org/annualmeeting2024

ABSTRACT SUBMISSION DATES
Opens: October 1, 2023
Closes: February 1, 2024
Submit your abstract here: asent.org/annualmeeting2024

PIPELINE SUBMISSION DATES
Opens: October 1, 2023
Closes: February 1, 2024
Submit your abstract here: asent.org/annualmeeting2024

OTHER ACTIVITIES
On March 11-12, The inaugural ASENT Clinical Trials Course will take place onsite. The Neurotherapeutics Drug Discovery and Development Course will run onsite March 12-15 as well.
## REGISTRATION RATES

<table>
<thead>
<tr>
<th></th>
<th>MEMBER RATES</th>
<th>NON MEMBER RATES</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAN Member</td>
<td>$250</td>
<td>$375</td>
</tr>
<tr>
<td>Academic Member</td>
<td>$275</td>
<td>$475</td>
</tr>
<tr>
<td>Advocacy Member</td>
<td>$175</td>
<td>$250</td>
</tr>
<tr>
<td>Clinician Member</td>
<td>$275</td>
<td>$475</td>
</tr>
<tr>
<td>Government Member</td>
<td>$275</td>
<td>$325</td>
</tr>
<tr>
<td>Industry Member</td>
<td>$425</td>
<td>$675</td>
</tr>
<tr>
<td>JSNT Member</td>
<td>$200</td>
<td>$275</td>
</tr>
<tr>
<td>LMIC Member</td>
<td>$150</td>
<td>$200</td>
</tr>
<tr>
<td>Retired Member</td>
<td>$250</td>
<td>$375</td>
</tr>
<tr>
<td>Trainee Member</td>
<td>$175</td>
<td>$250</td>
</tr>
</tbody>
</table>

Register at [asent.org/annualmeeting2024](https://asent.org/annualmeeting2024)
# MEETING OVERVIEW

## MONDAY, MARCH 11, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 5:30pm</td>
<td>ASENT Clinical Trials Course (APPLICATION ONLY)</td>
</tr>
<tr>
<td>5:30pm - 8:00pm</td>
<td>Reception and Dinner with Board and Program Committee and JSNT Delegates</td>
</tr>
</tbody>
</table>

## TUESDAY, MARCH 12, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30am - 12:00pm</td>
<td>ASENT Clinical Trials Course (APPLICATION ONLY)</td>
</tr>
</tbody>
</table>

## TUESDAY, MARCH 12, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 8:00am</td>
<td>Registration and Breakfast</td>
</tr>
<tr>
<td>8:00am - 8:15am</td>
<td>Presidential Welcome Remarks</td>
</tr>
</tbody>
</table>
| 8:15am - 10:15am | Symposium: **Fluid Biomarkers as endpoints for neurodegenerative diseases**  
This symposium is offered in partnership with the Japanese Society of Neurological Therapeutics. We are honored to have a long partnership with JSNT and pleased to present their delegate.  
**DESCRIPTION:** Fluid Biomarkers are being utilized to study neurodegenerative diseases, including Alzheimers and Parkinsons Disease.  
**CHAIR:** Larry Altstiel, MD, PhD, ProMIS Neurosciences  
**COCHAIR:** Gail Farfel, PhD, Consultant  
**FACULTY:**  
Dr. Ayami Okuzumi, Juntendo University School of Medicine, JSNT Presenter  
Robert Bowser, PhD Barrow Neurological Institute |
| 10:15am - 10:30am | Networking Break                                                      |
| 10:30am - 12:00pm | Symposium: **Platform Clinical Trials in Neurology**  
**DESCRIPTION:** The session will focus on how neurodegenerative disorders can benefit from platform designs using The HEALEY ALS Platform Trial as an example to showcase how the collaborative effort and enrollment in the trial can benefit neurotherapeutics trials.  
**CHAIR:** Merit Cudkowicz, MD, MSc, Harvard Medical School/MGH  
**COCHAIR:** Amir Tamiz, PhD, NINDS  
**PRESENTATIONS:**  
[The NINDS and Master Protocols for Platform Trials: Many Neurological Needs, So Little Time](#)  
Clinton Wright, MD, MS, NINDS  
[Healey ALS Platform Trials: Lessons and Future](#)  
Merit Cudkowicz, MD, MSc, Harvard Medical School/MGH  
[Statistical Science of Platform Trials: The Balance of Flexibility and Inference](#)  
Melanie Quintana, PhD, Berry Consultants  
**PANEL DISCUSSION INCLUDING:**  
Irfan Qureshi, MD, CMO, Biohaven  
Teresa Buracchio, MD, CDER, FDA |
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00pm - 1:30pm</td>
<td>Regency Ballroom Foyer</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>12:30pm - 1:30pm</td>
<td>TBD</td>
<td>Program Committee and Board Meeting</td>
</tr>
<tr>
<td>1:30pm - 3:00pm</td>
<td>Regency IV</td>
<td><strong>CONCURRENT Symposium: Exosome in Neurotherapeutics</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DESCRIPTION: Extracellular vesicles (EVs) have wide-ranging implications in numerous disease areas. Targeting these EVs as a therapeutic strategy is an ever increasing field. During this symposium speakers will look at EV biomarkers, EVs as therapeutics, and EVs for the clinical and preclinical diagnosis of Alzheimer’s disease and other neurological and psychiatric diseases.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHAIR: Dimitrios Kapogiannis, MD, National Institute on Aging</td>
</tr>
<tr>
<td></td>
<td></td>
<td>COCHAIR: Carolyn Tallon, PhD, ALTPEP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FACULTY:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neuronal-enriched extracellular vesicles provide biomarkers predicting future cognitive impairment and AD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carlos Nogueras-Ortiz, PhD, National Institute on Aging</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Characterization of ATP1A3 as a neuron-specific EV protein and its potential applications for clinical diagnosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>You Yang, PhD, Mayo Clinic College of Medicine and Science</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Inhibiting Extracellular Vesicle Biosynthesis as a Therapeutic Target for Alzheimer's Disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Meixiang Huang, PhD, Johns Hopkins Drug Discovery</td>
</tr>
<tr>
<td>1:30pm - 3:00pm</td>
<td>Regency I</td>
<td><strong>CONCURRENT Symposium: Digital Biomarkers in CNS clinical studies</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>DESCRIPTION: The field of neuroscience is rapidly advancing with groundbreaking technologies and methodologies. In recent years, the emergence of digital biomarkers has revolutionized clinical studies in Central Nervous System disorders. This session will delve into the promising role of digital biomarkers in CNS clinical studies, exploring their potential to enhance diagnosis, monitoring, and treatment evaluation. During this session, esteemed experts in the field will present their latest research and share insights on the application of digital biomarkers across a range of CNS disorders. Attendees will gain a comprehensive understanding of the opportunities and challenges associated with leveraging digital biomarkers in clinical research.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHAIR: Bibi Bielokova, MD, NIAID</td>
</tr>
<tr>
<td></td>
<td></td>
<td>COCHAIR: Sharon Tamir, MT-Pharma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FACULTY:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Developing Digital Technologies for CNS Clinical Studies: Regulatory Considerations</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jay Gupta, PhD, CDRH, U.S. Food and Drug Administration (FDA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wearable Sensors and Digital Health Technologies for Tracking Disease Progression in Neurological and Neuromuscular Disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. Ashkan Vaziri, PhD, Founder and CEO, BioSensics LLC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exploring Oculometrics as Digital biomarkers in CNS disorders</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rivka Kreitman, PhD, NeuraLight</td>
</tr>
<tr>
<td>3:00pm - 3:15pm</td>
<td>Regency Ballroom Foyer</td>
<td>Networking Break</td>
</tr>
<tr>
<td>Time</td>
<td>Venue</td>
<td>Event Description</td>
</tr>
<tr>
<td>-----------</td>
<td>---------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 3:15pm - 5:00pm | Regency I         | **CONCURRENT Symposium: Opportunities to streamline development of gene therapies for rare diseases**  
DESCRIPTION: A significant percentage of rare diseases affecting 30 million people in the US alone are neurological, and 90% of rare childhood disorders have major neurological effects. Many rare diseases stem from single-gene variations, they may be addressable using rapidly maturing genetic technologies, such as antisense oligonucleotides, small interfering RNAs, gene therapy and gene editing. Recent advances in gene therapies have encouraged the scientific community to pursue these treatments as disease modifying treatments that potentially bring significant benefit to the patients. This symposium will address end-to-end regulatory path for individualized gene therapies  
CHAIR: Gopa Raychaudhuri, PhD, Associate Director for Special Programs, FDA/CBER  
COCHAIR: Amir Tamiz, PhD, NINDS  
FACULTY:  
**Challenges in Bringing a Gene Therapy Product to the Global Marketplace: An Industry Perspective**  
Lawrence Stark, PhD, Novartis  
**Knowing your “why” can change the journey to gene therapy.**  
Gina Hann, Rare Village  
**Academic perspective on the development of gene therapy treatments for rare neurological disorders: How do we get these to patients?**  
Steven Gray, MD, UT Southwestern  
**Getting beyond “one disease at a time”: towards platform approaches to genetic therapies**  
Philip J. Brooks, PhD, NIH/NCATS |**Concurrent Symposium: Opportunities to streamline development of gene therapies for rare diseases**

3:15pm - 5:00pm | Regency IV | **CONCURRENT Symposium: Current Research and Advances in Multiple Sclerosis**  
DESCRIPTION: Microbial agents including viruses have long been incriminated as triggers in multiple sclerosis (MS). There is mounting evidence that EBV might play a role in MS pathogenesis. Stem cells transplantation therapy for MS is currently being evaluated in clinical trials including mesenchymal stem cell and autologus stem cells. The symposium will address advances in these three aspects of MS.  
CHAIR: Suhayl Dhib-Jalbut, MD, Rutgers School of Medicine  
COCHAIR: Steve Jacobson, PhD, NIH  
FACULTY:  
**Title TBD**  
Steve Jacobson, PhD, NINDS  
**BTK Inhibitors as a Treatment for Chronic Inflammation in Multiple Sclerosis**  
María Inés Gaitán, MD, NIH  
**Glial Cells as Therapeutic Targets in Progressive Multiple Sclerosis**  
Marjan Gharagozloo, Ph.D., Johns Hopkins |**Concurrent Symposium: Current Research and Advances in Multiple Sclerosis**

5:00pm - 6:00pm | Regency Ballroom Foyer | **Cocktail Reception** |**Cocktail Reception**
### TUESDAY, MARCH 12, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00pm - 8:00pm</td>
<td>ASENT Careers Dinner</td>
<td>Each year ASENT invites a selection of speakers to informally share the trajectory of their career. We ask our speakers to come with no slides and a willingness to answer questions as there are many early career attendees in the audience.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suhayl Dhib-Jalbut, MD, Rutgers School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gopa Raychaudhuri, PhD, Associate Director for Special Programs, FDA/CBER</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kevin Biglan, MD, MPH, Eli Lilly and Company</td>
</tr>
</tbody>
</table>

### WEDNESDAY, MARCH 13, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 8:00am</td>
<td>Registration and Breakfast</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00am - 8:30am</td>
<td>ASENT Business Meeting</td>
<td></td>
</tr>
<tr>
<td>8:30am - 10:00am</td>
<td>Symposium: Parkinson's disease biological staging and implications for therapeutic trials</td>
<td>DESCRIPTION: Biological staging of Parkinson's disease is being proposed with use of imaging and cerebrospinal fluid biomarkers and prodromal clinical features. There is momentum in the field to define Parkinson's disease according to biological markers rather than traditional clinical features. This session seeks to explore the scientific, clinical, and regulatory issues surrounding pathways for therapeutics development using this framework.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHAIR: Ludy Shih, MD, MMSc, FAAN, FANA, Boston University School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>COCHAIR: Kathleen Poston, M.D., M.S., Stanford University</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FACULTY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neuronal Synuclein Disease: Towards an Integrated Staging System to Accelerate Clinical Trials</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kathleen Poston, M.D., M.S., Stanford University</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Perspectives, challenges and opportunities for clinical trials, research, and advocacy in Lewy body dementia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jennifer Goldman, MD, MS, Lewy Body Dementia Association</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Optimizing drug development in Lewy Body Diseases: Biological characterization of PD and lessons from Alzheimer's disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Kevin Biglan, MD, MPH, Eli Lilly and Company</td>
</tr>
<tr>
<td>10:00am - 10:30am</td>
<td>Networking Break</td>
<td></td>
</tr>
<tr>
<td>10:30am - 11:00am</td>
<td>SPECIAL UPDATE: Long-COVID and neurodegenerative diseases</td>
<td>A major concern of the long-term consequences of COVID is the precipitation or acceleration of neurodegenerative diseases with cognitive dysfunction. The talk will review the current evidence, clinical and pathological manifestations, the pathophysiological mechanisms and potential modes of intervention. It will also discuss the need for future studies and clinical trials.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CHAIR: Debra J. Ehrlich, MD, MS, NINDS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>COCHAIR: Sharon Tamir, Mitsubishi Tanabe Pharma America</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FACULTY</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Avindra Nath, MD, NINDS</td>
</tr>
<tr>
<td>Time</td>
<td>Event Description</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>12:00pm - 1:00pm</td>
<td><strong>SATELLITE SYMPOSIUM</strong>&lt;br&gt;Clinilabs presents&lt;br&gt;The Patient Perspective on Parkinson's Disease Clinical Research&lt;br&gt;This satellite symposium will provide researchers with a direct patient perspective on participating in clinical trials. Patients will share their experiences and expectations to help guide the development of more patient-centric protocols in an effort to pave the way for improved enrollment and retention in Parkinson's clinical trials.&lt;br&gt;This discussion will be led by:&lt;br&gt;Angie Randazzo, PhD, Director, Patient Engagement &amp; Advocacy, Clinilabs</td>
<td></td>
</tr>
<tr>
<td>12:00pm - 1:30pm</td>
<td><strong>DEBATE:</strong> Amyloid Targeted Treatments for Alzheimer’s Disease: The Arguments For and Against&lt;br&gt;Collegial debate on the pros and cons of amyloid-targeting treatments for Alzheimer’s disease with 4 speakers discussing the science supporting (or not) the validity of amyloid as a therapeutic target and the data from the completed RCTs of newly approved amyloid antibodies (Lecanemab and Aducanumab) with a focus on the gaps in clinical data and the assessment of risks vs. benefits.&lt;br&gt;CHAIR: Madhav Thambisetty, MD, PhD, NIH&lt;br&gt;COCHAIR: Amir Tamiz, PhD, NIH&lt;br&gt;A rapid fire among 4 clinician scientists, up to 10 minutes each:&lt;br&gt;FOR: John Dickson, MD, PhD, Harvard&lt;br&gt;AGAINST: Alberto Espay, MD, University of Cincinnati&lt;br&gt;FOR: David C. Weisman, MD, Abington Neurological Associates&lt;br&gt;AGAINST: Madhav Thambisetty, MD, PhD, NIH&lt;br&gt;To be followed by rebuttals and a robust interactive discussion.</td>
<td></td>
</tr>
<tr>
<td>1:30pm - 3:00pm</td>
<td><strong>Pipeline Presentations</strong>&lt;br&gt;Submitted abstracts that most closely conform to the ASENT Abstract criteria, showcase new and emerging data with scientific or clinical impact and align with ASENT goals have been selected for a 10-minute oral presentation (including 5 minute Q&amp;A) at one of our Pipeline Presentation sessions.&lt;br&gt;Improvement in a plasma biomarker of neuroinflammation, Chitinase-3-like-protein (CHI3L1/YLK-40), in the CENTAUR trial&lt;br&gt;Presenter: Heather Vita, PhD, AMYLYX Pharmaceuticals&lt;br&gt;Bilateral intrastratial delivery of Life Edit CRISPR system (LEG-B) using AAV5 results in broad CNS biodistribution and expression of LEG-B in NHP brain regions critical for Huntington’s disease (HTT) pathology, and allele selective reduction of mutant HTT protein in a clinically relevant murine model&lt;br&gt;Presenter: Hanqian Mao, PhD, Life Edit Therapeutics&lt;br&gt;Effects of GLP-1 receptor agonist on chronic axonal damage, neurodegeneration, and cognitive function in relapsing-remitting MS (MSGLP): exploratory, open label, randomized controlled trial.&lt;br&gt;Presenter: Richard Imrich, PhD, Dsc, Biomedical Research Center, Slovak Academy of Sciences&lt;br&gt;BAER-101, a selective potentiator of α2- and α3-containing GABAA receptors, fully suppresses spontaneous cortical spike-wave discharges in Genetic Absence Epilepsy&lt;br&gt;Presenter: Amy Chappell, M.D., Avenue Therapeutics</td>
<td></td>
</tr>
</tbody>
</table>
### WEDNESDAY, MARCH 13, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Location/Session</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00pm - 3:30pm</td>
<td>Regency Ballroom Foyer</td>
<td>Networking Break</td>
</tr>
<tr>
<td>3:30pm - 5:00pm</td>
<td>Regency I</td>
<td><strong>Platform Presentations</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Submitted abstracts that most closely conform to the ASENT Abstract criteria, showcase novel design or concepts and align with ASENT goals may also be selected for a 10-minute oral presentation (including 2 minute Q&amp;A) at one of our Platform Presentation sessions.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Positive allosteric modulation of GABAA α5 receptors improves memory performance of rats with conditions of hippocampal hyperactivity</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Presenter:</strong> Ming-Teng Koh, Ph.D., Johns Hopkins University</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Baseline network predictor of the placebo response: Can susceptible individuals be identified before randomization?</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Presenter:</strong> János A. Barbero, The Feinstein Institutes for Medical Research</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bridging translational research to clinical research provides therapeutic opportunities to patients with a primary mitochondrial disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Presenter:</strong> Anne Chiaramello, Ph.D., George Washington University School of Medicine and Health Sciences</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ALT100, a designed peptide targeting α-sheet Amyloid-β oligomers, improves behavior in an ICV oligomeric Aβ mouse model</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Presenter:</strong> Carolyn Tallon, Ph.D., AltPep Corp.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Development of novel small molecules targeting neurotrophic HGF signaling for the treatment of Alzheimer’s, Parkinson’s, and ALS</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Presenter:</strong> Robert Taylor, Ph.D., Athira Pharma, Inc.</td>
</tr>
<tr>
<td>5:00pm - 6:00pm</td>
<td>Regency Ballroom Foyer</td>
<td><strong>Cocktail and Poster Reception</strong></td>
</tr>
</tbody>
</table>
## MEETING OVERVIEW

### WEDNESDAY, MARCH 13, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00pm - 8:00pm</td>
<td>Neurotherapeutics Dinner</td>
<td>This dinner symposium is a combined effort of the Training in Neurotherapeutics Discovery and Development Course and the ASENT2024 Annual Meeting. All participants are welcome to attend.</td>
</tr>
<tr>
<td>Regency I</td>
<td>Guest Speaker: Irfan Qureshi, M.D., CMO, Biohaven</td>
<td>CHAIR: Michael Rogawski, MD, PhD, University of California, Davis</td>
</tr>
</tbody>
</table>

### THURSDAY, MARCH 14, 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00am - 8:20am</td>
<td>Registration and Breakfast</td>
<td></td>
</tr>
<tr>
<td>Regency Ballroom Foyer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:20am - 8:30am</td>
<td>Presidential Closing Day Remarks</td>
<td></td>
</tr>
<tr>
<td>Regency I</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30am - 10:00am</td>
<td>Presidential Symposium: Pre-clinical to First in Human In Drug Development</td>
<td>DESCRIPTION: This fireside chat will feature speakers from both a small independent academic startup as well as a speaker from a large pharmaceutical company to compare and contrast the similarities and differences in the preclinical process and infrastructure when developing a neurotherapeutic. This discussion will be moderated by ASENT President Andrew Cole, MD.</td>
</tr>
<tr>
<td>Regency I</td>
<td></td>
<td>CHAIR: Nathan Fountain, MD, University of VA School of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FACULTY: Nathan Fountain, MD, University of Virginia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jim Doherty, PhD, Acumen Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>10:00am - 10:30am</td>
<td>Networking Break</td>
<td></td>
</tr>
<tr>
<td>Regency Ballroom Foyer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30am -12:00 pm</td>
<td>CONCURRENT Symposium: Novel Delivery Systems in CNS</td>
<td>DESCRIPTION: Oligonucleotides, antibodies, and gene therapies are increasingly poised to provide significant benefit for central nervous system (CNS) disorders. These modalities offer great promise to change the course of a disease. However, delivery of these therapeutics remains a significant challenge as they do not readily penetrate the blood brain barrier. Informed by fundamental multidisciplinary research in blood-brain barrier biology, protein engineering is identifying solutions that enable the delivery of these therapeutic modalities into the CNS. This symposium will highlight several innovative approaches to improve biotherapeutics delivery to the brain.</td>
</tr>
<tr>
<td>Regency I</td>
<td></td>
<td>CHAIR: Ben Deverman, PhD, MIT and Harvard</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CO-CHAIR: Amir Tamiz, PhD, NINDS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FACULTY: Transport Vehicle: Utilizing the Brain Vasculature for Delivering CNS Therapeutics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Joy Zuchero, PhD, Denali Therapeutics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AAVs engineered to bind Transferrin Receptor enable CNS-wide gene delivery</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ben Deverman, PhD, Broad Institute of MIT and Harvard</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Discovery and mechanism of action of cross-species BBB-penetrant capsids</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mathieu Nonnenmacher, PhD, Voyager Therapeutics</td>
</tr>
</tbody>
</table>
### THURSDAY, MARCH 14, 2024

<table>
<thead>
<tr>
<th>10:30am -12:00 pm</th>
<th>CONCURRENT Symposium: Animal Models in Neurotherapeutics: the good, the bad and the ugly.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regency IV</td>
<td>Description: A crucial component to drug discovery research relies on utilizing animal models to demonstrate efficacy in disease specific models. However, the choice of model to use has always been a difficult question to navigate given the wide variety of available models for any given neurological disease. This symposium aims to discuss the common pitfalls to avoid when utilizing animal models and provide discussion on what to consider when designing animal model experiments for drug development in the neurological space. Chair: Carolyn Tallon, PhD, AltPep</td>
</tr>
<tr>
<td></td>
<td>FACULTY: Perspectives and Paths Forward for overcoming the Preclinical to Clinical Translation conundrum in Alzheimer’s disease Therapy Development Stacey J. Sukoff Rizzo, PhD, University of Pittsburgh</td>
</tr>
<tr>
<td></td>
<td>Animal Models for Drug Development in Epilepsy: Challenges and Opportunities Cameron Metcalf, PhD, Anticonvulsant Drug Development Program, University of Utah</td>
</tr>
<tr>
<td></td>
<td>Why have all clinical trials in PD failed: are we using the wrong animal model or study design, or both? Charles K. Meshul, PhD, Oregon Health and Science University</td>
</tr>
</tbody>
</table>

|  | Meeting Concludes |
2024 POSTERS IN ORDER BY POSTER # 1-7

PLATFORM PRESENTATIONS

#1
BAER-101, a selective potentiator of α2- and α3-containing GABAA receptors, fully suppresses spontaneous cortical spike-wave discharges in Genetic Absence Epilepsy

Presenter: Amy Chappell, M.D., Avenue Therapeutics
Abstract Authors: Amy Chappell, Alexandra MacLean, Corinne Roucard, Alexis Evrard, Hugo Monchal

Platform Presentation

#2
Positive allosteric modulation of GABAA α5 receptors improves memory performance of rats with conditions of hippocampal hyperactivity

Presenter: Ming-Teng Koh, Ph.D., Johns Hopkins University
Abstract Authors: Ming Teng Koh, Sharon Rosenzweig-Lipson, Michela Gallagher

Platform Presentation

#3
Baseline network predictor of the placebo response: Can susceptible individuals be identified before randomization?

Presenter: János A. Barbero, The Feinstein Institutes for Medical Research
Abstract Authors: János Barbero, An Vo, Nha Nguyen, Yilong Ma, Shichun Peng, Chris Tang, Charalampos Tzoulis, David Eidelberg

Platform Presentation

#4
Bridging translational research to clinical research provides therapeutic opportunities to patients with a primary mitochondrial disease

Presenter: Anne Chiaramello, Ph.D., George Washington University School of Medicine and Health Sciences
Abstract Authors: Martine Uittenbogaard, Andrea Gropman, Anne Chiaramello

Platform Presentation

#5
ALT100, a designed peptide targeting α-sheet Amyloid-β oligomers, improves behavior in an ICV oligomeric Aβ mouse model

Presenter: Carolyn Tallon, Ph.D., AltPep Corp.
Abstract Authors: Carolyn Tallon, Chandresh Gajera, Chris Tran, Jeff Posakony, Charles Watt, Gill Block, Valerie Daggett

Platform Presentation

#6
Antisense oligonucleotides directed against a human endogenous retrovirus for treatment of Amyotrophic Lateral Sclerosis

Presenter: Kevon Sampson, National Institute of Neurological Disorders and Stroke, National Institutes of Health
Abstract Authors: Kevon Sampson, Wexue Li, Myoung Hwa Lee, Lisa Henderson, Avindra Nath

Poster Presentation

#7
Development of novel small molecules targeting neurotrophic HGF signaling for the treatment of Alzheimer’s, Parkinson’s, and ALS

Presenter: Robert Taylor, Ph.D., Athira Pharma, Inc.
Abstract Authors: Robert Taylor, Andree-Anne Berthiaume, Kayla Kleist, Sherif Reda, Sharay Setti, Jewel Johnston, Wei Wu, Kevin Church

Platform Presentation
MEETING OVERVIEW

2024 POSTERS

IN ORDER BY POSTER # 8-13

PIPELINE PRESENTATIONS

#8
Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator: Results from Phase 1 Single and Multiple Ascending Dose Studies

Presenter: Irfan Qureshi, M.D., Biohaven Pharmaceuticals
Abstract Authors: Bharat Awsare, Jason Lerner, Eric Ashbrenner, Heather Sevinsky, Michael Bozik, Steven Dworetzky, Lia Donahue, Randall Killingsworth, Bruno Francoeur, Irfan Qureshi

Poster Presentation

#9
BHV-7000, A Novel, Selective Kv7.2/7.3 Potassium Channel Activator, Demonstrates Dose-Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults

Presenter: Irfan Qureshi, M.D., Biohaven Pharmaceuticals
Abstract Authors: Jason Lerner, Bharat Awsare, Heather Sevinsky, Eric Ashbrenner, Randall Killingsworth, Racheal Kendrick, Emiel Vereycken, Nigel Colenbier, Caroline Neuray, Pieter van Mierlo, Jeremy Slater, David Wyatt, Irfan Qureshi, Steven Dworetzky, Michael Bozik

Poster Presentation

#10
Improvement in a plasma biomarker of neuroinflammation, Chitinase-3-like-protein (CHI3L1/Ylk-40), in the CENTAUR trial

Presenter: Heather Vita, Ph.D., AMYLYX Pharmaceuticals
Abstract Authors: Robert Bowser, Jiyan An, Lahar Mehta, Junliang Chen, Jamie Timmons, Merit Cudkowicz, Sabrina Paganoni, Heather Vita

Pipeline Presentation

#11
Bilateral intrastriatal delivery of Life Edit CRISPR system (LEG-B) using AAV5 results in broad CNS biodistribution and expression of LEG-B in NHP brain regions critical for Huntington’s disease (HTT) pathology, and allele selective reduction of mutant HTT protein in a clinically relevant murine model

Presenter: Hanqian Mao, Ph.D., Life Edit Therapeutics
Abstract Authors: Hanqian Mao, Logan Brown, Nancy Cheng, Alexandra Crawley, Ritika Jiani, Jamie Moy, Ariel Vitenzon, Kathryn Woodburn

Pipeline Presentation

#12
Effects of GLP-1 receptor agonist on chronic axonal damage, neurodegeneration, and cognitive function in relapsing-remitting MS (MSGLP): exploratory, open label, randomized controlled trial.

Presenter: Richard Imrich, Ph.D., DSc., Biomedical Research Center, Slovak Academy of Sciences
Abstract Authors: Richard Imrich, Adela Penesová, Miroslav Vlček, Žofia Rádiková, Andrea Havranová, Pavol Šiarnik, Miroslava Hardoňová, Branislav Kollár, Peter Turčáni

Pipeline Presentation

#13
From standardization to specificity: a retrospective analysis of adverse event classification in neurological clinical research

Presenter: Katherine Landry, National Institutes of Health
Abstract Authors: Katherine Landry, Matthew Gooden, Sandra Martin, Henry Roberts, Lauren Reoma

Poster Presentation
MEETING OVERVIEW

2024 POSTERS
IN ORDER BY POSTER # 14-20

#14
Active Neurogenic Modulation of Cerebral Blood Flow to Alter Flow Dynamics in Patients with Neurodegenerative Diseases and in Aging Adults

Presenter: Robert D. Black, Ph.D., Scion Neurostim
Abstract Authors: Robert D. Black, Ph.D.
Poster Presentation

#15
Investigator-initiated Clinical Trials for Neurological Diseases in Japan: Pipeline and Support Structures

Presenter: Ken Sakushima, M.D., M.P.H., Ph.D., Hokkaido University Hospital
Abstract Authors: Ken Sakushima, Harumasa Nakamura, Kazuo Fujihara
Poster Presentation

#16

Presenter: Jaya Viswanathan, Ph.D., National Institute on Aging, National Institutes of Health
Abstract Authors: Jaya Viswanathan, Maria Fe Lanfranco Gallofre, Zane Martin, Suzana Petanceska, Shreya Chakroborty, Lorenzo Refolo
Poster Presentation

#17
Development of a Composite Biomarker for Amyotrophic Lateral Sclerosis: Experimental Approach and Progress to Date

Presenter: Heather Vita, Ph.D., AMYLYX Pharmaceuticals
Abstract Authors: Jamie Timmons, Evan Mizerak, Joshua Cohen, Justin Klee, Sasha Bakhru, James Berry, Robert Bowser, Heather Vita
Poster Presentation

#18
AGB101 for the treatment of neuropsychiatric symptoms in Parkinson’s disease

Presenter: Arnold Bakker, Ph.D., Johns Hopkins University
Abstract Authors: Arnold Bakker, Gregory Pontone, Richard Mohs, Michela Gallagher
Poster Presentation

#19
Decoding therapeutic signatures: The contribution of pharmaco-EEG in profiling compounds with varied mechanisms of action.

Presenter: Julien Volle, Ph.D., SynapCell
Abstract Authors: Julien Volle, Manon Villalba, Clélia Allioux, Baptiste Caraballo, Carine Dumont, Eloïse Gronlier, Davy Darankoum, Corinne Roucard, Yann Roche, Chloé Habermacher
Poster Presentation

#20
Translational Evaluation of Acute 4-Aminopyridine (4-AP) Treatment to Reduce Axon Damage after Experimental Traumatic Brain Injury

Presenter: Kryslaine L. Radomski, Ph.D., Uniformed Services University of the Health Sciences
Abstract Authors: Kryslaine Radomski, Xiaomei Zi, Regina Armstrong
Poster Presentation
MEETING OVERVIEW

2024 POSTERS
IN ORDER BY POSTER # 21-27

#21
GlyB4: A novel biologic to stop neuroinflammation and neurodegeneration in ALS and Alzheimer’s disease
Presenter: Jeffrey A. Loeb, M.D., Ph.D., University of Illinois at Chicago
Abstract Authors: Jeffrey Loeb, Michael Flavin, Fei Song
Poster Presentation

#22
Human endogenous retrovirus-K (HERV-K) env knockdown by AAV9-mediated shRNA attenuates amyotrophic lateral sclerosis (ALS)-like symptoms in transgenic mice
Presenter: Myoung-Hwa Lee, Ph.D., National Institute of Neurological Disorders and Stroke, National Institutes of Health
Abstract Authors: Myoung-Hwa Lee, Wenxue Li, Kevon Sampson, Melina Jones, Joseph Steiner, Avindra Nath
Poster Presentation

#23
Beyond the diagnosis: Advancing quality of life for those with progressive diseases through innovative housing and technology solutions.
Presenter: Theresa Whitlock-Wild, Matt's Place Foundation
Abstract Author: Theresa Whitlock-Wild
Poster Presentation

#24
Repurposing on old drug for a new disease-modifying therapy for epileptic disorders with brain calcifications
Presenter: TJ Stalvey, M.P.H., M.B.A., ZY Therapeutics
Abstract Authors: TJ Stalvey, Jeffrey Loeb
Poster Presentation

#25
The NIH HEAL Initiative/National Institute of Neurological Disorders and Stroke’s Early Phase Pain Investigation Clinical Network (EPPIC-Net): Year 4 Update.
Presenter: Rebecca Hommer, M.D., National Institutes of Health
Abstract Authors: Rebecca Hommer, Kevin Jones, Marlene Peters-Lawrence, Clinton Wright
Poster Presentation

#26
Novel mitochondrial protective agent for Parkinson’s Disease targeting the PINK1/LRRK2 axis
Presenter: Sherine S. Chan, Ph.D., Neuroene Therapeutics
Abstract Authors: Sherine Chan, Emmaline Bendell, Jesse McClure, James Chou
Poster Presentation

#27
The NIH HEAL Initiative Preclinical Screening Platform for Pain (PSPP)
Presenter: Sarah A. Woller, Ph.D., National Institute of Neurological Disorders and Stroke, National Institutes of Health
Abstract Authors: Sarah Woller, Shalini Sharma, Christopher Conrad, Vicki Brings, Smriti Iyengar
Poster Presentation
MEETING OVERVIEW

2024 POSTERS
IN ORDER BY POSTER # 28-31

#28
Neuropathology Evaluation of Olney Lesions in Regulatory Drug Development Toxicology Studies
Presenter: Deepa B. Rao, BVSc, M.S., Ph.D., Greenfield Pathology Services, Inc.
Abstract Authors: Deepa Rao, David Hawver, David Hall, William Jordan
Poster Presentation

#29
NeuroNEXT: A Summary of the First 12 Years & A Look Towards the Future
Presenter: Christopher S. Coffey, Ph.D., University of Iowa
Abstract Authors: Christopher Coffey, Megan McCabe, Aleks Videnovic, Dixie Ecklund, Marianne Chase, Joan Ohayon, Sophie Cho, Amy Tsou, Brenda Thornell, David Klements, Michele Costigan, Maria Houghton, Michael Moshinsky, Emily Roberts, Merit Cudkowicz
Poster Presentation

#30
A phase 2 trial of T-DXd for tumor-agnostic HER2-positive brain and leptomeningeal metastases
Presenter: Alice R. Tang, MBBS, Dana–Farber Cancer Institute
Abstract Author: Alice Tang
Poster Presentation

#31
The NIH HEAL Pain Therapeutics Development Program RFA-NS-24-019
Presenter: Matthew Rice, Ph.D., National Institute of Neurological Disorders and Stroke, National Institutes of Health
Abstract Authors: Matthew Rice, Carolyn Bondar, Mary Ann Pelleymounter
Poster Presentation
PROGRAM COMMITTEE

CHAIRS
Sharon Tamir, Chair
*Mitsubishi Tanabe Pharma America*
Dietrich Haubenberger, MHSc, MD
*Neurocrine*

MEMBERS
C. Anthony Altar, PhD
*Splice Therapeutics*
Deena Andreola
*Takeda*
Enrique Carrazana, MD
*Neurelis*
Suhayl Dhib-Jalbut, MD,
*Rutgers-Robert Wood Johnson Medical School*
Debra Ehrlich, MD, MS
*NINDS*
Gail Farfel, PhD
*Consultant*

Aditya Joshi, MD
*University of Pennsylvania*
Michelle Manzo, MPH
*UCB*
Ludy Shih, MD, MMSc
*Boston University Medical Campus*
Amir Tamiz, PhD
*NINDS*
Carolyn Tallon, PhD
*AltPep*
Abstract Deadline
January 22, 2024
asent.org/
annualmeeting2024

Early Bird Deadline
December 31, 2023
asent.org/
annualmeeting2024

Hotel Reservation Deadline
February 10, 2024
asent.org/
annualmeeting2024

Register at asent.org/annualmeeting2024